23:35 , Jan 5, 2018 |  BC Extra  |  Company News

Reports: Acorda exploring sale

Acorda Therapeutics Inc. (NASDAQ:ACOR) gained $2.50 (12%) to $23.55 on Friday after media reports that the company is exploring a possible sale. Acorda declined to comment. In November, Acorda discontinued development of Parkinson's disease candidate tozadenant...
00:02 , Dec 1, 2017 |  BC Week In Review  |  Clinical News

Acorda discontinues PD candidate Tozadenant

Acorda Therapeutics Inc. (NASDAQ: ACOR) discontinued development of Parkinson's disease candidate tozadenant (SYN115) "based on new information" related to cases of agranulocytosis disclosed on Nov. 15 that were possibly related to tozadenant and in some...
17:54 , Nov 20, 2017 |  BC Extra  |  Clinical News

Acorda discontinues PD candidate tozadenant

Acorda Therapeutics Inc. (NASDAQ: ACOR) discontinued development of Parkinson's disease candidate tozadenant (SYN115) "based on new information" related to cases of agranulocytosis disclosed last week that were possibly related to tozadenant and in some cases...
05:04 , Nov 17, 2017 |  BC Week In Review  |  Clinical News

Acorda discloses safety concerns for PD candidate tozadenant

Acorda Therapeutics Inc. (NASDAQ:ACOR) disclosed cases of agranulocytosis that were possibly related to treatment with Parkinson's disease candidate tozadenant (SYN115) and in some cases associated with sepsis and death. Among about 890 patients who received the...
23:03 , Nov 15, 2017 |  BC Extra  |  Clinical News

Acorda falls on tozadenant safety concerns

Acorda Therapeutics Inc. (NASDAQ:ACOR) lost $11.20 (40%) to $17 on Wednesday after disclosing cases of agranulocytosis that were possibly related to treatment with Parkinson's disease candidate tozadenant (SYN115) and in some cases associated with sepsis...
23:10 , Oct 6, 2017 |  BioCentury  |  Finance

Coasting on catalysts

While buysiders do not expect any sector-moving milestones in the wake of a catalyst-heavy third quarter, they will have at least 21 Phase III milestones and 23 PDUFA dates on their radar. But the biggest...
19:04 , Aug 11, 2017 |  BC Week In Review  |  Company News

Investor urges Acorda to sell

In a letter, Scopia Capital Management LP urged the board of Acorda Therapeutics Inc. (NASDAQ:ACOR) to consider a sale of the company. Scopia owns 16.5% of Acorda. Following a March court ruling that drastically shortened U.S....
23:10 , Aug 7, 2017 |  BC Extra  |  Company News

Investor urges Acorda to sell

In a letter, Scopia Capital Management LP urged the board of Acorda Therapeutics Inc. (NASDAQ:ACOR) to consider a sale of the company. Scopia owns 16.5% of Acorda. Following a March court ruling that drastically shortened U.S....
12:29 , May 26, 2017 |  BC Week In Review  |  Company News

Corvus and Genentech expand 2015 deal, add second combo trial

Corvus Pharmaceuticals Inc. (NASDAQ:CRVS) said the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) will manage a Phase Ib/II trial evaluating Corvus’ CPI-444 in combination with Genentech’s Tecentriq atezolizumab in non-small cell lung cancer (NSCLC) patients...
19:42 , Apr 7, 2017 |  BC Week In Review  |  Company News

Acorda patent challenge and restructuring news

The U.S. District Court for the District of Delaware invalidated four of the five Orange Book-listed patents protecting Acorda’s multiple sclerosis drug Ampyra dalfampridine on grounds of obviousness. Acorda said it plans to appeal the...